Patents Represented by Attorney David R. Kurlandsky
-
Patent number: 8153587Abstract: A method for orally administering a parathyroid hormone, PTH, comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of calcitonin. The method according to the invention allows for the oral administration of PTH without the hypercalcemia, hypercalcuria and nephrolithiasis side effects.Type: GrantFiled: January 28, 2008Date of Patent: April 10, 2012Assignee: Novartis AGInventors: Joseph M Ault, Moise Azria, Simon D Bateman, James F McLeod
-
Patent number: 8124795Abstract: A process for modifying the crystal habit of acicular drug substances, crystals obtained by such a process, and particular crystal forms or modifications of mycophenolic acid or mycophenolate sodium are provided, as well as pharmaceutical compositions comprising the crystals, methods of treatment and uses thereof.Type: GrantFiled: August 4, 2011Date of Patent: February 28, 2012Assignee: Novartis AGInventors: Sabine Pfeffer, Dierk Wieckhusen
-
Patent number: 7749954Abstract: The present invention relates to a novel use of calcitonin in osteoarthritis, and to methods of treating and/or preventing osteoarthritis in mammals, particularly humans.Type: GrantFiled: July 22, 2004Date of Patent: July 6, 2010Assignee: Novartis AGInventors: Moise Azria, Claus Christiansen, Simon David Bateman, Shoufeng Li
-
Patent number: 6942876Abstract: The present invention is directed to novel combinations of anti-epileptic compounds that demonstrate pain alleviating properties, with compounds selected from the group consisting of analgesics, NMDA receptor antagonists, and NSAIDs and pharmaceutical compositions comprising same. It has been discovered that the administration of anti-epileptic compounds that demonstrate pain alleviating properties in these novel combinations results in an improved reduction in the frequency and severity of pain. It is also believed that the incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel pharmaceutical compositions to treat pain in mammals.Type: GrantFiled: February 13, 2002Date of Patent: September 13, 2005Assignee: Warner-Lambert CompanyInventors: Leslie Magnus-Miller, Douglas A. Saltel
-
Patent number: 6835751Abstract: The compounds of the instant invention are bicyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.Type: GrantFiled: January 21, 2004Date of Patent: December 28, 2004Assignee: Warner-Dambert Company LLCInventors: Justin Stephen Bryans, David Clive Blakemore, Simon Andrew Osborne, Jean-Marie Receveur
-
Patent number: 6828341Abstract: Described are cyclohexylamine derivatives of Formula I and pharmaceutically acceptable salts thereof, wherein R1, g, *, R, V, B, E, Y, G, H, X1, and d are as defined in the description. The compounds of Formulas I, VI, and VIa are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.Type: GrantFiled: March 27, 2002Date of Patent: December 7, 2004Assignee: Warner-Lambert CompanyInventors: Russell Joseph DeOrazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer
-
Patent number: 6794402Abstract: Described are bicycle-substituted cyclohexylamines of Formula I and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are defined in the specification.Type: GrantFiled: November 12, 2002Date of Patent: September 21, 2004Assignee: Warner-Lambert CompanyInventors: Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
-
Patent number: 6783952Abstract: Soluble &agr;2&dgr; sub-type polypeptides. Methods for cloning, expression and purification of freely soluble &agr;2&dgr; subtype polypeptides. A method for the screening of ligands which bind to soluble &agr;2&dgr; subtype polypeptides.Type: GrantFiled: September 16, 1999Date of Patent: August 31, 2004Assignee: Warner-Lambert CompanyInventors: Jason Peter Brown, François Bertelli
-
Patent number: 6784208Abstract: The compounds of formula I-IV: wherein n is an integer of from 1 to 4, or pharmaceutically acceptable salts thereof are useful to prevent and treat visceral pain and gastrointestinal disorders.Type: GrantFiled: January 25, 2002Date of Patent: August 31, 2004Assignee: Warner-Lambert CompanyInventors: Maria Chovet, Laurent Diop
-
Patent number: 6765022Abstract: Described are cyclobexylamine derivatives of Formula I, Formula II, or Formula III and their pharmaceutically acceptable salts thereof: The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's disease. The substituents are described in the specification.Type: GrantFiled: December 2, 2002Date of Patent: July 20, 2004Assignee: Warner-Lambert CompanyInventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
-
Patent number: 6734306Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein X1 and X2 are halo; R1 and R2 are independently hydrogen or C1-4 alkyl; R3 and R4 are each hydrogen or halo; and R5 is (a) —C3-9 diazacycloalkyl optionally substituted with C5-11 azabicycloalkyl; (b) —C3-9 azacycloalkyl-NH—(C5-11 azabicycloalkyl optionally substituted with C1-4 alkyl); (c) —NH—C1-3 alkyl-C(O)—C5-11 diazabicycloalkyl; (d) —NH—C1-3 alkyl-C(O)—NH—C5-11 azabicycloalkyl, the C5-11 azabicycloalkyl being optionally substituted with C1-4 alkyl; (e) —C3-9 azacycloalkyl optionally substituted with C3-9 azacycloalkyl; or (f) —NH—C1-5 alkyl-NH—C(O)—C4-9 cycloalkyl-NH2. These compounds are useful for the treatment of medical conditions mediated by bradykinin such as inflammation, allergic rhinitis, pain, etc.Type: GrantFiled: December 5, 2001Date of Patent: May 11, 2004Assignee: Pfizer, Inc.Inventors: Yasuhiro Katsu, Makoto Kawai, Hiroki Koike, Seiji Nukui
-
Patent number: 6713490Abstract: This invention provides a compound which is (R)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1-hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof. The compound is useful for the treatment of disease conditions caused by overactivation of NMDA NR2B receptor such of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine, or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: April 14, 2003Date of Patent: March 30, 2004Assignee: Pfizer, Inc.Inventor: Mitsuhiro Kawamura
-
Patent number: 6713461Abstract: This invention relates to a complex of eletriptan and a sulphobutylether-beta-cyclodextrin, or a pharmaceutically acceptable salt thereof, and to processes for the preparation of, pharmaceutical formulations including, and the uses of, such a complex.Type: GrantFiled: June 29, 2000Date of Patent: March 30, 2004Assignee: Pfizer Inc.Inventor: Anne Billotte
-
Patent number: 6710054Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof, wherein Y1, Y2, Y3 and Y4 are independently selected from N, CH, etc.; R1 is H, C1-8 alkyl, etc.; Q1 is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N, and S, etc.; A is 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; B is C1-6 alkylene optionally substituted with an oxo group, etc.; W is NH, O, etc.; R2 is H, C1-4 alkyl, etc.; Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected form O, N and S, etc.; L is halo, C1-4 alkyl, etc.; m is 0, 1 or 2; R3 and R4 are independently selected from H and C1-4 alkyl; R5 is H, C1-4 alkyl; etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic ring or tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, etc.Type: GrantFiled: October 15, 2001Date of Patent: March 23, 2004Assignee: Pfizer IncInventors: Kazunari Nakao, Yoshiyuki Okumura, Miyako Matsumizu, Naomi Ueno, Yoshinobu Hashizume, Tomoki Kato, Akiyoshi Kawai, Yoriko Miyake, Seiji Nukui, Katsuhiro Shinjyo, Kana Taniguchi
-
Patent number: 6710190Abstract: The invention is a novel series of compounds which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: November 21, 2001Date of Patent: March 23, 2004Assignee: Warner-Lambert CompanyInventor: Po-Wai Yuen
-
Patent number: 6703522Abstract: GABA-related pro-drugs of the formula (III) are provided that when administered to humans or other mammals provide an increased duration of active compound in the plasma compared to compounds of corresponding structure in which labile groups are not present. The compounds are of the formula (III) In the above formula: P represents hydrogen or methyl; Q represents a labile amine- or amide-forming organic group that becomes removed in the human or animal body; R1 represents straight or branched C2-C6 alkyl, C3-C6 cycloalkyl or phenyl; R2 represents hydrogen or methyl; and R3 represents hydrogen, methyl or carboxyl; and R4 represents hydrogen or a labile ester-forming group selected from substituted and unsubstituted C1-C6 alkyl, benzyl and phenyl groups that become removed in the human or animal body. In the above formula when R1 is phenyl, R2, R3 and R4 are not simultaneously hydrogen.Type: GrantFiled: November 21, 2002Date of Patent: March 9, 2004Assignee: Warner-Lambert CompanyInventors: David Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
-
Patent number: 6689906Abstract: The invention is a novel series of cyclic amino acids which are useful in the treatment of epilepsy, faintness attacks, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, gastrointestinal disorders such as irritable bowel syndrome (IBS), and inflammation, especially arthritis. A pharmaceutical composition containing a compound of the invention as well as methods of preparing the compounds and novel intermediates useful in the preparation of the final compounds are included.Type: GrantFiled: April 19, 2002Date of Patent: February 10, 2004Assignee: Warner-Lambert CompanyInventors: Justin Stephen Bryans, David Clive Blakemore, Simon Andrew Osborne, Jean-Marie Receveur
-
Patent number: 6686373Abstract: This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein the dashed lines represent optional double bonds; C1, C2, C3 and C4 are carbon atom; R1 is C1-4 alkyl; R2 is H, amino, etc.; R3 is H, halo-CH2—, C2-8 alkyl or Q1-, wherein said C2-8 alkyl is optionally substituted with up to 3 substituents selected from halo, C1-3 alkyl, R4(R5)N, etc.; R4 is H, C1-7 alkyl, etc.; R5 is H, C1-7alkyl, etc.; R6 and R7 are independently selected from H and C1-4 alkyl; R8 is aryl or heteroaryl; Q1 is a 4-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4 alkyl, etc.; Y5, Y6, Y7 and Y8 are hydrogen; Y1, Y2, Y3 and Y4 are independently selected from hydrogen, halo, etc.Type: GrantFiled: July 9, 2002Date of Patent: February 3, 2004Assignee: Warner-Lambert Company LLCInventors: Kiyoshi Kawamura, Sachiko Mihara, Seiji Nukui, Chikara Uchida
-
Patent number: 6683101Abstract: Described are heterocycle-substituted cyclohexylamines of formula (I), and their pharmaceutically acceptable salts thereof.Type: GrantFiled: December 3, 2002Date of Patent: January 27, 2004Assignee: Warner-Lambert CompanyInventors: Russell Joseph Deorazio, Sham Shridhar Nikam, Ian Leslie Scott, Brian Alan Sherer, Lawrence David Wise
-
Patent number: 6653313Abstract: The present invention relates to compounds of the formula wherein each A is independently halo; Y is —(CH2)m—, —C(O)— or —S(O)—; R1 and R2 are independently C1-4 alkyl; R3 is substituted azacycloalkyl etc.; R4 is phenyl substituted at the 2-position with a substituent selected from substituted C1-7 alkyl, substituted C1-7 alkoxy, amine, etc; R5 is hydrogen or C1-4 alkyl; m is 0, 1 or 2; and n is 0, 1, 2, 3, 4 or 5. The present invention also relates to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders.Type: GrantFiled: July 11, 2001Date of Patent: November 25, 2003Assignee: Warner-Lambert Company LLCInventors: Mitsuhiro Kawamura, Makoto Kawai, Yuji Shishido, Tomoki Kato, Yasuhiro Katsu, Takafumi Ikeda, Noriaki Murase